MICHELLE TALAG: Open Payments
NPI 1114319738 · SEAFORD, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,724 in 87 payments from 27 companies in 2025. Trend: 2023 $1,278 · 2024 $1,680 · 2025 $1,724
Food & beverage: $1,724
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $191 |
| Novo Nordisk Inc | 9 | $183 |
| AstraZeneca Pharmaceuticals LP | 6 | $150 |
| ABBVIE INC. | 13 | $145 |
| Lilly USA, LLC | 6 | $120 |
| PFIZER INC. | 4 | $85 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $82 |
| Verona Pharma, Inc. | 4 | $79 |
| GENZYME CORPORATION | 3 | $78 |
| UCB, Inc. | 3 | $75 |
Products named: MOUNJARO, Rybelsus, OTEZLA, REPATHA, UBRELVY, JARDIANCE, Ohtuvayre, DUPIXENT.
Industry payments across DE — which companies pay providers there.
